Orient Europharma Co. Ltd.

点击蓝字GBIHealth关注我们SUBSCRIBE to us据GBI SOURCE数据库全球交易板块，2023年3月，国内生物制药企业披露的许可引进（License-in）交易、对外许可（License-out）、本土许可交易交易数量相当，分别为4笔、5笔和3笔。此外，本月还有1则交易终止，Leap Therapeutics宣布百济神州放弃行使DKN-01在亚洲的开发和商业化权利。表1. 2023年3月许可引进交易表2. 2023年3月对外许可交易表3. 2023年3月本土许可交易来源：GBI SOURCE 全球交易板块点击“阅读原文”登录GBI SOURCE数据库全球交易板块2023年3月许可引进交易License-in亘喜生物获得Seagen细胞疗法许可权■  许可方：Seagen INC.■  被许可方：亘喜生物■  产品/技术：五款细胞疗法亘喜生物在提交美国证券交易委员会的文件中透露，已与美国生物技术公司Seagen达成产品全球非独占许可协议。该交易于2023年3月8日达成，就在几天前，辉瑞宣布以430亿美元收购Seagen。据悉，亘喜生物将获得Seagen旗下五款细胞疗法的开发和商业化权利，其中每个许可都是非排他的和可分许可的。*登录GBI SOURCE数据库全球交易板块了解更多丽珠医药获Onconic钾离子阻滞剂大中华区权益■  许可方：Onconic Therapeutics Inc.■  被许可方：丽珠医药■  产品/技术：Zastaprazan丽珠医药发布公告称，与韩国Onconic Therapeutics Inc.就后者开发的Zastaprzan签署了一项在大中华区的独占许可授权协议。根据协议，丽珠医药获得在中国大陆和港澳台内开发、制造和商业化钾离子竞争性酸阻滞剂 （P-CAB）Zastaprazan的权利，公司将向Onconic支付1500万美元不可退回的首付款，在许可产品开发及上市销售阶段，将向Onconic支付技术转移费用、相应的开发里程碑及销售里程碑金共计不超过1.125亿美元。许可产品在许可区域获批上市销售后，丽珠医药应根据协议向Onconic支付相应的销售提成。 *登录GBI SOURCE数据库全球交易板块了解更多赛神医药与Secarna共同开发中枢神经系统反义寡核苷酸药物■  许可方：Secarna Pharmaceuticals■  被许可方：赛神医药■  产品/技术：中枢神经系统反义寡核苷酸药物赛神医药和德国公司Secarna Pharmaceuticals宣布达成了一项研究合作和期权协议。根据协议，Secarna将使用其核酸发现和开发平台LNAplus，针对赛神医药选择的靶点生成和分析反义寡核苷酸（ASO）候选药物用于治疗中枢神经系统（CNS）疾病。此外，赛神医药将有权获得产品在全球范围内的独家开发和商业化权利。Secarna Pharmaceuticals是欧洲领先的独立下一代反义药物发现和开发公司，致力于为“不可成药”的靶点提供新策略。*登录GBI SOURCE数据库全球交易板块了解更多艾博兹医药公布GPC3靶向多肽候选药物开发计划■  许可方：RayzeBio Inc■  被许可方：艾博兹医药■  产品/技术：GPC3靶向多肽候选药物艾博兹医药宣布了针对GPC3的首创新型多肽候选药物的开发计划。根据现有协议，艾博兹医药正在从RayzeBio获取其专利GPC3靶向多肽候选产品的许可。艾博兹医药将负责该产品在大中华地区的临床开发和商业化。此外，艾博兹医药和RayzeBio已建立合作伙伴关系，获得RayzeBio一系列产品在大中华区的独家开发和商业化权利。*登录GBI SOURCE数据库全球交易板块了解更多扫描二维码，登录GBI SOURCE全球药品数据库，点击全球交易版块了解更多信息。 2023年3月对外许可交易License-out杨森获百奥赛图RenLite授权，开发全人共轻链抗体等生物制品■  许可方：百奥赛图■  被许可方：杨森■  产品/技术：RenLite平台百奥赛图与强生旗下杨森制药签订非独家授权协议。根据协议，百奥赛图授予杨森及其关联公司全球非独家许可，使用百奥赛图专有RenLite平台及其相关知识产权，以发现、研究、开发、生产和商业化针对不限数量药物靶点，可用于任何用途的全人共轻链抗体和其他生物制品。该许可协议由强生创新主导。 *登录GBI SOURCE数据库全球交易板块了解更多安基生技与Avenue达成罕见病药欧美专属授权■  许可方：安基生技■  被许可方：Avenue Therapeutics■  产品/技术：AJ201安基生技新药（安基）宣布与美国那斯达克上市生技新药公司Avenue Therapeutics Inc.签订AJ201罕见疾病——肯尼迪氏症小分子新药欧美专属许可协议。安基可获得含签约金、里程碑金等在内的最高2.5亿美元授权金，此外还可以超两位数百分比的销售额抽成分润。此次是中国台湾生技产业临床Ⅱa早期授权案，也是近年来最大的罕见疾病新药授权案。*登录GBI SOURCE数据库全球交易板块了解更多高光制药与美国BIOHAVEN就TLL-041达成独家许可■  许可方：高光制药■  被许可方：Biohaven Ltd■  产品/技术：TLL-041Biohaven Ltd宣布与杭州高光制药有限公司达成在大中华区域以外的独家开发与许可协议，引进高光制药研发的TLL-041 。Biohaven将支付2000万美元首付款（现金+股票）、9.5亿美元里程碑款及多层次、比例不等的销售分成。Biohaven将在2023年启动临床I期，双方将在全球协作进行临床开发 。 *登录GBI SOURCE数据库全球交易板块了解更多中国生物制药旗下公司F-star授予武田双特异抗体平台权益■  许可方：F-Star Therapeutics Inc.■  被许可方：武田■  产品/技术：双特异抗体平台中国生物制药宣布旗下公司F-star Therapeutics, Inc.与武田就新一代癌症免疫疗法双特异性抗体订立第二份许可协议。根据许可协议，F-star将收取许可使用费，授予武田全球独家授权，以采用F-star专有的Fcab及mAb2平台研究、开发及商业化一种针对癌症免疫疗法标靶的双特异性抗体。武田将负责该协议下的所有研究、开发及商业化活动。F-star将获得一笔预付许可费，并有权收取潜在未来开发及商业化里程碑付款，以及基于每年净销售额的许可使用费。*登录GBI SOURCE数据库全球交易板块了解更多兆科眼科授出近视新药NVK002韩国分销权■  许可方：兆科眼科■  被许可方：Kwangdong Pharmaceutical Co.,Ltd.■  产品/技术：NVK002兆科眼科宣布已与韩国Kwangdong Pharmaceutical Co.,Ltd.（KDP）订立一份有关NVK002（一种硫酸阿托品外用眼部溶液）的分销及供应协议。根据协议，公司授予KDP独家权利，于南韩进口、宣传、分销、营销及出售NVK002。公司将收取一笔前期款项，以及若干监管及销售里程碑款。*登录GBI SOURCE数据库全球交易板块了解更多扫描二维码，登录GBI SOURCE全球药品数据库，点击全球交易版块了解更多信息。 2023年3月本土许可交易健康元获太景流感药TG-1000独家权利■  许可方：太景■  被许可方：健康元■  产品/技术：TG-1000健康元宣布已与太景医药研发（北京）有限公司以及太景生物科技股份有限公司（以下合称：太景） 签署《专利实施许可暨商业化合作合同》。太景将授予健康元旗下PA核酸内切酶抑制剂TG-1000产品，以及衍生开发的其他药物及产品在中国大陆、香港及澳门特别行政区的独家开发、制造和商业化权利。健康元将向太景支付2000万首付款、相应里程碑款，以及最高不超过11%的销售提成费。合同生效后，TG-1000国内临床试验将由健康元接手主导推进。*登录GBI SOURCE数据库全球交易板块了解更多友华生技获得昂瑞生物潜在首创药物独家权益■  许可方：昂瑞生物■  被许可方：友华生技■  产品/技术：Oregovomab海普瑞药业集团控股子公司昂瑞生物与友华生技医药股份有限公司签订许可协议，授予后者免疫疗法候选药物Oregovomab独家权利。友华生技负责该候选药物在中国台湾的商业化，包括相关的监管申请、必要的临床试验等工作。昂瑞生物还授予友华生技在中国香港和中国澳门独家销售、营销和分销权的优先购买权。许可总交易额最高可达1120万美元。同时，友华生技以未来中国台湾地区Oregovomab药品销售均价的一定比例为约定价格，向昂瑞生物购买该药物。*登录GBI SOURCE数据库全球交易板块了解更多艾力斯获和誉医药新一代EGFR TKI ABK3376中国权益■  许可方：和誉医药■  被许可方：艾力斯■  产品/技术：ABK3376艾力斯医药与和誉医药签署许可协议。和誉医药授予艾力斯新一代小分子表皮生长因子受体酪氨酸激酶抑制剂（EGFR TKI）ABK3376在中国（包括中国大陆、香港、澳门和台湾地区）研究、开发、制造、使用以及销售的独家许可。艾力斯有权在达到行权条件时选择行使海外权益，将授权区域扩大至全球范围。艾力斯将就此项授权向和誉医药支付最高不超过1.879亿美元的首付款、开发及销售里程碑付款以及相应比例净销售额的许可提成费。*登录GBI SOURCE数据库全球交易板块了解更多2023年3月终止交易百济神州不再引进Leap的DKK1抗体■  原许可方：Leap Therapeutics■  被许可方：百济神州■  产品/技术：DKN-01美国公司Leap Therapeutics宣布，百济神州放弃行使其DKK1单抗DKN-01在亚洲的开发和商业化权利。不过，两家公司仍将继续合作开展一项DKN-01联合替雷利珠单抗和化疗用于一线治疗癌症患者的临床试验。 *登录GBI SOURCE数据库全球交易板块了解更多点击“阅读原文”登录GBI SOURCE数据库全球交易板块全新上线GBI SOURCE 药品数据库全球交易板块全新上线可视化分析图表！可按年/季度/月份浏览不同交易类型的交易趋势、交易金额平均值、交易机构类型、交易治疗领域等维度信息，一键掌握最新交易动态！点击文末“阅读原文”登录数据库立即体验扫描二维码登录 GBI SOURCE 数据库全球交易版块了解更多信息相关推荐*点击图片阅读详情*点击图片阅读详情点击 阅读原文 登录GBI SOURCE数据库全球交易板块

SHENZHEN, China, March 28, 2023 /PRNewswire/ -- OncoVent Co., Ltd. ("OncoVent"), a majority-controlled subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company"), yesterday entered into a license agreement with Orient EuroPharma Co., Ltd. ("OEP"). According to the terms of the agreement, OncoVent agreed to grant exclusive rights to OEP, which will be responsible for the commercialization of oregovomab, an immunotherapy drug candidate, in Taiwan, including related regulatory applications and necessary clinical trials. OncoVent is entitled to a number of payments from OEP under the license agreement, including a one-off non-refundable upfront payment upon the effective date of the license agreement, multiple regulatory milestone payments, and multiple commercial milestone payments, in a total transaction amount of up to US$11.2 million. OEP also agreed to purchase oregovomab from OncoVent at a price equal to an agreed percentage to the average sale price of oregovomab in Taiwan. In addition, OncoVent granted OEP the right of first refusal for the exclusive sales, marketing, and distribution right in Hong Kong and Macau. Oregovomab, a murine monoclonal antibody and a first-in-class anti-CA125 immunotherapy drug candidate, is currently being evaluated in a global Phase III trial using study drugs produced by Cytovance Biologics Inc, a wholly-owned subsidiary of the Company and a leading contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry. Prior to this, a Phase II clinical study of oregovomab in combination with standard chemotherapy for the first-line treatment of patients with advanced primary ovarian cancer was already completed. Results from the Phase II clinical trial showed that the safety and efficacy of the combination in patients with advanced primary ovarian cancer were in line with expectations, with the median progression-free-survival (PFS) of the oregovomab plus chemotherapy cohort significantly improved to 41.8 months, compared with 12.2 months with the chemotherapy-only regimen, with a hazard ratio (HR) of 0.46 (95% confidence interval [CI]: 0.28, 0.77). It also showed a significant improvement in overall survival (OS) with an HR of 0.35 (95% Cl: 0.16, 0.76). Ovarian cancer is ranked the eighth most common cancer in women globally and the first-line treatment for this disease has not changed for many years. Oregovomab has obtained Orphan Drug Designations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The first patient in a Phase III clinical trial of oregovomab was dosed in the U.S. in 2020. This global pivotal trial is expected to enroll 602 patients from 190 clinical sites in 17 countries and regions. As of the date of the announcement, the Phase III clinical trial of oregovomab has enrolled 534 subjects globally, of which 21 subjects are from Taiwan. Mr. Calvin Tsai, Chief Executive Officer of OEP, said, "we have been actively expanding our oncology portfolio through R&D collaborations and in-licensing, in order to address unmet medical needs in a broad range of tumor types and bring renewed hope to cancer patients in the Asia Pacific region. Hepalink is a leading multinational biopharmaceutical company dual-listed in Hong Kong and mainland China. Its subsidiary, OncoVent, possesses a monoclonal antibody (mAb) technology platform and advanced biotechnologies for the development of oncotherapeutic vaccines and immuno-oncologic combination therapies. It is our pleasure to enter into this collaboration with Hepalink. We believe oregovomab can potentially improve the treatment outcomes for patients with advanced primary ovarian cancer. This collaboration with OncoVent not only strengthens our oncology portfolio, but also serves our overarching objective of advancing oncologic therapeutics." Ms. Tao Han, Chief Business Officer of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. and Chief Executive Officer of OncoVent Co., Ltd, commented, "having established itself in the oncology field for over 20 years, OEP is a multinational pharmaceutical company with integrated capabilities in R&D, manufacturing and commercialization, as well as a highly experienced team in the Asia Pacific region. We are glad to have entered into this strategic agreement with OEP as it will allow us to jointly develop and commercialize oregovomab, a candidate drug with promising therapeutic potential, and explore the drug's additional therapeutic utility for a broader population of cancer patients. Moving forward, Hepalink will continue to seek partnering opportunities to accelerate the expansion of its innovative drug business and develop a diverse range of commercial capabilities." About Orient EuroPharma Established in 1982 and officially listed on the Taipei Exchange in 2003, OEP provides prescription drugs, cancer drugs, nutrition and healthcare for young children and adults, medical and beauty care and other products. It has research and development centers in Taiwan and the United States, and two pharmaceutical factories in Taiwan for U.S. FDA-approved oral finished doses and highly allergenic injections. It is a multinational pharmaceutical manufacturer with research and development, production and sales capabilities as well as sales teams covering Southeast Asia, Hong Kong, Mainland China and the United States. With over 20 years of experience in the cancer field and solid business and sales teams in Taiwan, Hong Kong, Singapore, the Philippines and Malaysia. OEP currently sells cancer drugs such as "Vinorelbine" oral capsules for non-small cell lung cancer and breast cancer, and "Pamorelin" long-acting injections for prostate cancer. About OncoVent OncoVent Co., Ltd. was established in July 2016 and located in the Shenzhen Qianhai Development Zone. OncoVent is leveraging its technology platform of monoclonal antibodies (mAb) to develop clinical-stage therapeutic vaccines and immuno-oncology combination therapies. At present, a number of the OncoVent's drug candidates are already in clinical development. About Hepalink Established in 1998 in Shenzhen, China, Hepalink (002399.SZ, 09989.HK) is a leading multinational biopharmaceutical company dual-listed in Hong Kong and mainland China, with its core business in heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs. These three synergistic business segments are driven by the mission of addressing patients' unmet medical needs and bringing safe and effective therapies and services to patients around the world. To learn more, please visit: SOURCE Shenzhen Hepalink Pharmaceutical Group Co., Ltd.